Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives
- 30 June 2010
- journal article
- Published by Elsevier BV in European Journal of Medicinal Chemistry
- Vol. 45 (6), 2299-2306
- https://doi.org/10.1016/j.ejmech.2010.02.005
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Hybrid pharmacophore design and synthesis of isatin–benzothiazole analogs for their anti-breast cancer activityBioorganic & Medicinal Chemistry, 2009
- Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung CancerCurrent Medicinal Chemistry, 2009
- Targeted therapy for hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2009
- Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screeningCA: A Cancer Journal for Clinicians, 2009
- Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathwaysBreast Cancer Research and Treatment, 2008
- Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase InhibitorsJournal of Medicinal Chemistry, 2008
- Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase InhibitorsJournal of Medicinal Chemistry, 2007
- Discovery ofN-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-Aminoindazole-Based Orally Active Multitargeted Receptor Tyrosine Kinase InhibitorJournal of Medicinal Chemistry, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular PropertiesCancer Research, 2006